CLINICAL TRIALS EnteroMedic Inc., Roseville, a developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, said Thursday that following a recent meeting with the Food and Drug Administration to discuss the company's Empower obesity study results, the company intends to submit an Investigational Device Exemption application in the first quarter for a clinical trial to support a possible premarket approval application for the next-generation Maestro RC System in the treatment of morbid obesity.
PERSONNEL ValueVision Media, Eden Prairie, named Bob Ayd as president. He has been working as a consultant, and previously worked at QVC and Macy's.
